Background/Aims: CD24 is a highly glycosylated mucin-like antigen on the cell surface, which has recently emerged as a novel oncogene and metastasis promoter. We performed bioinformatics analysis to investigate whether CD24 can serve as a prognostic indicator in breast cancer. Methods: CD24 expression was assessed using SAGE Genie tools and Oncomine analysis. The PrognoScan database, Kaplan-Meier Plotter, and bc-GenExMiner were used to identify the prognostic roles of CD24 in breast cancer. Results: We found that CD24 was more frequently overexpressed in breast cancer than in normal breast tissue and correlated with worse prognosis. Meanwhile, high CD24 expression was associated with increased risk of HER2, basal-like, triple-negative breast cancer, and higher Scarff-Bloom-Richardson grade. Data mining in multiple big databases confirmed a positive correlation between CD24 mRNA expression and SDC1 mRNA expression in breast cancer tissue. Conclusions: Our findings suggest that CD24 overexpression is more common in breast cancer than in corresponding normal tissue. In addition, CD24 and SDC1 can serve as prognostic indicators for breast cancer. However, large-scale and comprehensive research is needed to further confirm these results.
CD24 is a Potential Biomarker for Prognosis in Human Breast Carcinoma
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Introduction
Breast cancer is one of the most frequently diagnosed malignancies and is a leading cause of cancer-related death among women worldwide [1] [2] [3] . Despite advances in early clinical diagnosis and treatment strategies, the prognosis of breast cancer remains poor [4] [5] [6] . Therefore, identifying sensitive and specific biomarkers for prognosis is urgently required.
Cluster of differentiation (CD) 24 is a small glycosyl phosphatidylinositol (GPI)-linked membrane glycoprotein (27) (28) (29) (30) amino acids in length) with glycosylation sites that bind P-selectin [7, 8] . High expression levels of CD24 have been identified in various types of cancers-such as breast, prostate, pancreas, ovary, colorectal, and bladder cancers-and indicate poor prognosis [9] [10] [11] [12] . CD24 has also been demonstrated to promote tumor cell proliferation, invasion, and metastasis in many types of cancers [3, 13, 14] . Also targeting CD24 for treatment of colorectal and pancreatic cancer using monoclonal antibodies or small interfering RNA reduce the tumor burden in tumor bearing mice [15] . Moreover, tumorigenesis and metastasis were reduced in CD24 knockout mice exposed to chemical carcinogens. Together, these findings indicate that CD24 may act not only as a potential therapeutic target, but also as a novel prognostic biomarker in cancer. In contrast, several studies revealed that absence or low expression of CD24 might be associated with tumor proliferation, invasiveness, or metastasis in breast cancer [16, 17] .
Thus, in this study, we evaluated the significance of CD24 mRNA expression in human breast cancer by using The Cancer Genome Atlas (TCGA) data portal. The present study was performed to determine the expression pattern, potential function, and distinct prognostic value of CD24 in breast cancer by pooling all currently available data.
Materials and Methods

SAGE analysis for CD24 expression
All available published SAGE data on normal and malignant human tissues were assessed for CD24 gene expression [37] [38] [39] . The CD24 gene expression profiles were visually displayed using SAGE Genie tools (http://www.ncbi.nlm.nih.gov/SAGE/).
Oncomine database analysis
Oncomine database (https://www. oncomine.org/resource/login.html), an online tumor microarray database, was used to determine the transcription levels of CD24 in breast cancer. The expression fold change of CD24 in clinical cancer specimens compared to normal controls was obtained as the parameters of p-value <1E-4, fold change >2, and gene ranking in the top 10%. The co-expression profile of the CD24 gene in breast cancer was assessed and displayed as a heat map.
Prognoscan database analysis
The correlation between overall survival (OS) and CD24 mRNA expression was assessed using an online database, PrognoScan database (http://www.abren.net/PrognoScan/). This database is a powerful platform for evaluating potential tumor markers and therapeutic targets. To evaluate the OS of patients with breast cancer, patient samples were divided into two groups by median expression (high vs. low expression) and analyzed using PrognoScan. HR with 95% confidence intervals (CI) and cox p-values were also computed. A p-value < 0.05 was considered statistically significant.
Kaplan-Meier plotter analysis
Kaplan-Meier Plotter (http://kmplot.com/analysis/) is an online database of published microarray datasets that assess the effect of 54, 675 genes on survival using 10, 461 cancer samples (5, 143 breast, 1, 816 ovarian, 2, 437 lung, and 1, 065 gastric cancer). We used the Kaplan-Meier plotter to assess the correlation between RFS and CD24 mRNA expression in patients with breast cancer. The hazard ratio (HR) with 95% confidence intervals (CI) and log rank p-value were also computed.
Breast Cancer Gene-Expression Miner v4.0 and UCSC Xena
We used Breast Cancer Gene-Expression Miner v4.0 (bc-GenExMiner v4.0)-a statistical mining tool of published annotated genomic data including 36 annotated genomic datasets and 5861 breast cancer patients [40, 41] -to evaluate the expression of CD24 mRNA in breast cancer, as well as its association with prognosis. We also used the correlation module to assess the correlation between genes or identified clusters of correlated co-expressed genes located in the same chromosomal region. The heat map and the correlation between CD24 and co-expressed genes in the same patient cohort were further verified and analyzed using UCSC Xena (http://xena.ucsc.edu/).
Results
CD24 transcript expression in breast cancer
Because CD24 is a GPI-anchored cell surface protein, its expression profile was determined by performing SAGE Digital Gene Expression. Our analysis revealed that expression levels of CD24 were higher in brain, retina, thyroid, lung, breast, pancreas, and skin cancer tissues, compared with their corresponding normal tissues (Fig. 1 ). Oncomine analysis of cancer vs. normal tissue revealed that CD24 mRNA was significantly over-expressed in male breast carcinoma, medullary breast carcinoma, invasive ductal breast carcinoma, and invasive breast carcinoma (Table 1 , Fig. 2 ).
Genetic alterations of CD24 and clinicopathological parameters in breast cancer patients
As shown in Table 2 , we performed Welch's test, using bcGenExMiner, to compare the transcription levels of CD24 among groups of patients, according to different clinicopathological characteristics. Our results demonstrated that there was no significant difference between the ≤ 51 years old and > 51 years old groups. Breast cancer patients with positive nodal status showed higher CD24 mRNA levels than those with negative nodal status. Estrogen receptor (ER) and progesterone receptor (PR) 
status were confirmed to correlate negatively with CD24 expression. Conversely, CD24 mRNA levels were higher in patients with human epidermal growth factor receptor 2 (HER2) positive tumors than in those with HER2-negative tumors ( Table  2 , Fig. 3 ). Between-group comparison also demonstrated significantly higher CD24 mRNA expression in cancers of the basal-like subtype than other subtypes and in triple-negative breast cancer (TNBC) than in non-TNBC (Table 2 , Fig. 3 ). Among tumors with different ScarffBloom-Richardson (SBR) grades (Fig. 3) , there was a global significant difference in CD24 expression, but the difference was not significant when individual groups were compared (SBR1 vs. SBR2, SBR1 vs. SBR3, and SBR2 vs. SBR3, p>0.05).
Association of CD24 expression and prognosis in breast cancer patients
PrognoScan database analysis showed that overexpression of CD24 correlated with low overall survival rates in patients with breast cancer (HR =1.18, 95% CI 1.08-1.30, p =0.000226) (Fig. 4) . KaplanMeier analysis revealed that high levels of CD24 mRNA correlated with a shorter relapse-free survival (RFS) (Fig. 5) . By performing data mining in bc-GenExMiner, we pooled previously available annotated genomic data to analyze the relationship between CD24 expression and metastatic relapse-free survival (MRFS). High levels of CD24 expression were associated with a higher risk (Fig. 6A) . Similarly, high CD24 expression was also associated with worse MRFS (HR =1.15, 95% CI 1.02-1.30, p =0.0272) (Fig. 6B) .
Co-expression of CD24 mRNA
The co-expression of CD24 was analyzed by Oncomine (Fig. 7A) . The co-expression profile of CD24 was identified with a big cluster of 567 genes across 30 breast carcinomas (Fig. 7A) [18] . A highly correlated gene was Syndecan-1 (SDC1), which can enhance multiple oncogene expression in breast cancer [19] [20] [21] [22] . Data mining in bc-GenExMiner 4.0 confirmed the positive correlation between CD24 and SDC1 mRNA (Fig.  7B) . Analysis of breast cancer patient data in the TCGA database using UCSC Xena (http:// xena.ucsc.edu/) further confirmed this positive correlation (Fig. 7C-D) . These findings suggest that CD24 might be closely related to SDC1 signaling pathways in breast cancer.
Discussion
CD24 is a heavily glycosylated mucin-like membrane protein that acts as a ligand for P-selectin, which is usually defined as a cancer stem cell marker in multiple types of solid tumors [23] [24] [25] [26] . Previous studies have shown that abnormal overexpression of CD24 is an unfavorable prognostic factor during carcinogenesis in various neoplasms [10, 15, 23, 27, 28] . Meanwhile, CD24 can upregulate the activity of STAT3 and the expression of prototype STAT3-regulated genes [29] . Furthermore, CD24 is associated with HER2 expression and HER2-Akt signaling activity, which can confer resistance to HER2-targeting treatments in HER2-positive cancer [30] . However, the prognostic significance of CD24 expression in breast cancer is still unclear.
In the current study, we evaluated databases on gene expression with clearly defined parameters between tumor and normal tissues. Our analysis using the TCGA database revealed that CD24 mRNA expression was higher in breast cancer tissue than in corresponding normal tissue. Furthermore, Oncomine analysis of cancer vs. normal tissue displayed that CD24 mRNA was significantly overexpressed in male breast carcinoma, medullary breast We next investigated the association of CD24 expression with prognosis by using the Kaplan-Meier Plotter, PrognoScan, and bc-GenExMiner. The pooled results revealed that high CD24 expression correlated with shorter OS and RFS. In addition, our data mining and meta-analysis suggested that high CD24 expression also correlated with an increased risk of metastatic relapse and significantly shorter MRFS among patients with breast cancer. These findings demonstrate that the expression level of CD24 might be a useful marker of prognosis in breast cancer.
Through co-expression and correlation analysis, we observed that CD24 might be closely related to the SDC1 signaling pathways in breast cancer. In fact, SDC1 can act as a cell surface adhesion molecule required for the maintenance of cell morphology and interaction with the surrounding microenvironment [31, 32] . Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion, and angiogenesis, and is associated with responses to chemotherapy and with prognosis in multiple solid and hematological cancers [33] [34] [35] . Ning Yang et al. found that SDC1 is preferentially expressed in breast carcinoma stromal fibroblasts that can promote the assembly of an architecturally abnormal ECM that is permissive of directional migration and invasion of carcinoma cells [36] . These results indicated that CD24 expression might regulate the tumor migration and invasion associated with SDC1 expression. So CD24 and SDC1 may serve as common prognostic indicators for breast cancer.
In summary, overexpression of CD24 was more common in breast cancer than in corresponding normal tissues and was associated with a worse prognosis. Additionally, SDC1 may be used as a prognostic marker in breast cancer together with CD24, large-scale and comprehensive studies are needed to confirm our findings and determine the clinical utility of CD24 in evaluating breast cancer prognosis.
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